Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
It has not been approved by the Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease
At present there are two classes of drug that potentiate the incretin effect as a means of improving glycemic control in type 2 diabetes
BENEFITS Triple receptor activation studied for simultaneous GLP-1, GIP, and glucagon engagement Metabolic research explored in Phase 2 clinical trials with notable body-composition results Glucagon component linked to thermogenesis and energy-expenditure pathways Next-generation compound investigated as an advancement over dual-agonist approaches Comparative pharmacology assessed alongside mono- and dual-agonists in research settings WHAT RESEARCHERS LOOK AT Triple-agonist binding affinity across GLP-1, GIP, and glucagon receptors Additive effects of glucagon-receptor activation on energy expenditure Dose-response and tolerability profiling from clinical-trial data Comparative outcomes vs tirzepatide and semaglutide Pharmacokinetic profiling and receptor selectivity QUICK SPECS Form: Lyophilized peptide powder Net per vial: 10 mg Purity: 99% (HPLC verified) Identity: MS-verified (per COA) Storage: 28C, protect from light and moisture Reconstitution: Use bacteriostatic water (sold separately) IDENTITY BASICS CAS: 2381089-83-2 Classification: Triple GLP-1/GIP/glucagon receptor agonist WHY CHOOSE DURHAM PEPTIDES FOR RETATRUTIDE
We utilize a base of lactated ringers, a solution specifically formulated to replenish essential fluids and electrolytes
Supplements are no substitute for a healthy diet
TLR2 Pep-Orid-Liposome Showed Potent Efficacy for AML Therapy in luc-Molm13 Xenograft NSG Mouse Model In Vivo To evaluate the efficacy of TLR2 pep-orid-liposome in vivo, we established an AML xenograft mouse model using luciferase-Molm13 cells in NSG mice
